Singapore markets close in 1 hour 29 minutes
Straits Times Index
3,296.19 -17.86 (-0.54%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,231.76 -404.46 (-2.06%) FTSE 100
8,395.62 -28.58 (-0.34%) Bitcoin USD
71,101.99 +4,384.23 (+6.57%) CMC Crypto 200
1,525.53 +36.99 (+2.48%)
PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta - Jakarta Delayed price. Currency in IDR
Add to watchlist
As of 02:21PM WIB. Market open.
| Previous close | 1,530.00 |
| Open | 1,535.00 |
| Bid | 1,510.00 x 0 |
| Ask | 1,515.00 x 0 |
| Day's range | 1,490.00 - 1,535.00 |
| 52-week range | 1,375.00 - 2,160.00 |
| Volume | |
| Avg. volume | 33,970,360 |
| Market cap | 69.846T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 24.31 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 38.00 (2.68%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Business Wire
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.